Skip to main content

Table 2 Period of breast cancer follow-up after treatment to monitor the presence of recurrent metastatic diseases

From: Metabolic comorbidities and the association with risks of recurrent metastatic disease in breast cancer survivors

Follow-up (month) N (%)
6–12 2 (0.2%)
13–24 135 (12.5%)
25–36 198 (18.3%)
37–48 277 (25.6%)
49–60 155 (14.3%)
>  61 314 (29.0%)